We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Analysis & Separations

Stay up to date on the topics that matter to you

N4 Pharma

N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.

Latest N4 Pharma Content

Product News

N4 Pharma Announces Collaboration With SRI To Target and Treat Cells in the Human Body That Have Been Previously Unreachable

N4 Pharma Plc, the company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI.

Never miss a story

with the Breaking Science News daily newsletter